<DOC>
	<DOCNO>NCT02808013</DOCNO>
	<brief_summary>Prospective , Randomized , Double-Blind , Placebo Controlled clinical trial study efficacy safety NDS-446 ( 500 mg/cap ) Men 45 year age old moderate severe low urinary tract symptom ( LUTS )</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety NDS-446 Men With Lower Urinary Tract Symptoms ( LUTS )</brief_title>
	<detailed_description />
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>1 . Men ≥45 year age . 2 . LUTS , base IPSS total score ≥8 &lt; 25 3 . Peak urinary flow rate ( Qmax ) ≥4 ≤15 mL/sec screen 4 . Post Void Residual ( PVR ) urine volume ≤ 200 mL screen 5 . PSA level screen &lt; 10 ng/mL . Subjects PSA &gt; 4ng/mL &lt; 10 ng/mL eligible prostate cancer rule 6 . Subjects understand speak English 7 . Able willing give inform consent comply study protocol procedure ( diary study tool ) . 1 . Not suitable medical intervention ( e.g. , require TURP , etc . ) 2 . History interstitial cystitis , bladder stone , urethral stricture , current prostatitis , acute urinary retention require catheterization last 3 month , condition suspect cause LUTS BPH 3 . Screening serum Creatinine ( Cr ) liver function test [ ALT ( SGPT ) , AST ( SGOT ) ] &gt; 3 time upper limit normal ( ULN ) confirm second measurement . 4 . Cancer prostate bladder history current diagnosis . 5 . Prostate nodule ( ) screen digital rectal exam ( DRE ) . 6 . Prior surgical procedure urinary tract TURP , laser prostatectomy , photovaporization prostate 7 . No minimally invasive surgery prostate TUMT TUNA within last 6 month . 8 . Active urinary tract infection . 9 . Unstable uncontrolled medical psychiatric condition . 10 . Abnormal screen labs &gt; 2 time upper limit normal ( ULN ) [ parameter list exclusion criterion # 3 ] 11 . Myocardial infarction CVA within past 90 day . 12 . Requiring ongoing administration antibiotic , antifungal , antiviral , chemotherapy , steroidal immunosuppressive treatment . 13 . Requiring chronic administration aspirin dose &gt; 81 mg/day . 14 . Known hypersensitivity study drug ingredient ( ) allergy berry . 15 . Use following medication : alpha blocker ( 28 day screen ) , herbal nutritional BPH supplement ( 28 day screen ) , OAB medication ( 28 day screen ) , 5 alpha reductase inhibitor ( 175 day screen ) , PDE5 inhibitor ( permit need erectile dysfunction , exceed 1 dose per week dose within 5 day visit ) 16 . Use investigational agent ( drug , biologic , device , etc . ) within 30 day screen 17 . Any reason condition judgment Clinical Investigator ( ) may put subject unacceptable risk may preclude subject understand comply study 's requirement .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>